Hookipa Pharma Inc (NASDAQ:HOOK)’s traded shares stood at 1.26 million during the last session, with the company’s beta value hitting 0.76. At the close of trading, the stock’s price was $1.32, to imply an increase of 38.95% or $0.37 in intraday trading. The HOOK share’s 52-week high remains $105.00, putting it -7854.55% down since that peak but still an impressive 45.45% since price per share fell to its 52-week low of $0.72. The company has a valuation of $15.92M, with an average of 0.15 million shares in intraday trading volume over the past 10 days and average of 47.18K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Hookipa Pharma Inc (HOOK), translating to a mean rating of 2.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give HOOK a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.04.
Hookipa Pharma Inc (NASDAQ:HOOK) trade information
After registering a 38.95% upside in the last session, Hookipa Pharma Inc (HOOK) has traded red over the past five days. The 5-day price performance for the stock is 57.12%, and 28.16% over 30 days. With these gigs, the year-to-date price performance is -34.33%. Short interest in Hookipa Pharma Inc (NASDAQ:HOOK) saw shorts transact 12919.0 shares and set a 0.32 days time to cover.
The extremes give us $3 and $3 for target low and target high price respectively. As such, HOOK has been trading -127.27% off suggested target high and -127.27% from its likely low.
Hookipa Pharma Inc (HOOK) estimates and forecasts
The rating firms project that company’s revenue will shrink -69.28% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 3.38M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 3.38M.Earnings reports from the last fiscal year show that sales brought in 36.6M and 1.29M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -90.78% before jumping 161.63% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 32.13% for the past 5-year period. While 2025 is set for a 11.24% return in earnings, projections for the next 5 years are at 26.11% annually.
HOOK Dividends
Hookipa Pharma Inc has its next earnings report out on 2025-Feb-27. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Hookipa Pharma Inc (NASDAQ:HOOK)’s Major holders
Hookipa Pharma Inc insiders hold 2.00% of total outstanding shares, with institutional holders owning 58.63% of the shares at 59.83% float percentage. In total, 58.63% institutions holds shares in the company, led by ECOR1 CAPITAL, LLC. As of 2024-06-30, the company held over 5.72 million shares (or 4.5597% of shares), all amounting to roughly $3.38 million.
The next major institution holding the largest number of shares is ARTAL GROUP S.A. with 5.67 million shares, or about 4.5191% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.35 million.
